drugset / Trial / NCT00439244

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

NCT00439244

Phase 3 Completed 412 enrolled Novartis
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the effects of zoledronic acid administered at the same time with teriparatide compared to zoledronic acid alone and teriparatide alone on bone mineral density (BMD) gain in the lumbar spine and total hip

Timeline

Start
2006-12
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Teriparatide Protein / enzyme biologic 20 ug Subcutaneous
Subject Zoledronic acid Other / unclassified 5 mg Intravenous

Indications